Picture of Crispr Therapeutics AG logo

CRSP Crispr Therapeutics AG Cashflow Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousLarge CapNeutral

Annual cashflow statement for Crispr Therapeutics AG, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

2019
December 31st
2020
December 31st
2021
December 31st
2022
December 31st
2023
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:10-K10-K10-K10-K10-K
Standards:
USG
USG
USG
USG
USG
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line66.9-349378-650-154
Depreciation
Non-Cash Items33.567.911611067
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital-48.433.426.919.8-194
Change in Accounts Receivable
Change in Prepaid Expenses
Change in Payable / Accrued Expenses
Change in Other Liabilities
Net Change in Other Assets & Liabilities
Cash from Operating Activities56.7-238539-496-260
Capital Expenditures-6.68-18.4-81.7-37.2-12
Purchase of Fixed Assets
Other Investing Cash Flow Items8.01-523-954-221387
Sale/Maturity of Investment
Purchase of Investments
Cash from Investing Activities1.32-541-1,035-259375
Net Issuance / Retirement of Stock
Cash from Financing Activities4311,01625138.662.7
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash489237-246-716177